Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
APPLICATION OF CHAF1A AS ACTIVATION TARGET FOR LATENT HIV-1 INFECTION
Document Type and Number:
WIPO Patent Application WO/2022/077727
Kind Code:
A1
Abstract:
Provided is an application of CHAF1A as an activation target for latent HIV-1 infection. The largest subunit of chromatin assembly factor CAF-1, CHAF1A, can significantly repress the expression of HIV-1 and promote latent HIV-1 infection. The removal of CHAF1A enables re-expression of latent HIV-1, and furthermore, in superposition with conventional latent infection activators such as TNFα, SAHA, and JQ-1, is able to activate the viral latent reservoir. With the development of latent infection-activating drugs targeting CHAF1A, it is expected that the latent virus is more fully activated and it is killed using the human immune system, thus reducing the latent reservoir of the virus in the body of a patient, or even removing it.

Inventors:
ZHANG HUI (CN)
MA XIANCAI (CN)
Application Number:
PCT/CN2020/133163
Publication Date:
April 21, 2022
Filing Date:
December 01, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV SUN YAT SEN (CN)
International Classes:
C12N15/87; A61K45/00; A61P31/18; C12N15/867; C12Q1/6851; C12Q1/70
Domestic Patent References:
WO2018089592A12018-05-17
WO2018081197A12018-05-03
Foreign References:
CN108704135A2018-10-26
CN110475567A2019-11-19
CN111110848A2020-05-08
CN106176753A2016-12-07
CN107596372A2018-01-19
CN109620954A2019-04-16
CN111544429A2020-08-18
Other References:
SHERAZ KHAN;MAZHAR IQBAL;MUHAMMAD TARIQ;SHAHIDM. BAIG;WASIM ABBAS: "Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins", CLINICAL EPIGENETICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 10, no. 1, 5 February 2018 (2018-02-05), London, UK, pages 1 - 19, XP021253267, ISSN: 1868-7075, DOI: 10.1186/s13148-018-0441-z
Attorney, Agent or Firm:
YOGO PATENT AND TRADEMARK AGENCY LIMITED COMPANY (CN)
Download PDF: